Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05972174 · ClinicalTrials.gov registry record · Phase 1
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
A Phase 1 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,504
- Enrollment target
NCT05972174 is a Phase 1 study that has completed, run by ModernaTX. The registered enrollment target is 1,504 participants.
The verdict
NCT05972174, a Phase 1 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,504 participants
- Enrollment target
Study Summary
The purpose of this Phase 1/2 study is to generate sufficient safety and immunogenicity data of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large Phase 3 trial with one selected vaccine candidate. The study will be conducted in 2 Parts (Part A and Part B) that will enroll and run concurrently. Part A of the study will evaluate 4 vaccine candidates (H5N8, H7N9, H5 only, and H7 only). Part B of the study will evaluate a single vaccine candidate (H5 only-CG).
Interventions
- BIOLOGICAL mRNA-1018 for H5N8
- BIOLOGICAL mRNA-1018 for H7N9
- BIOLOGICAL mRNA-1018 for H5 Only
- BIOLOGICAL mRNA-1018 for H7 Only
- BIOLOGICAL mRNA-1018 for H5 Only-CG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,504 participants |
| Start Date | 2023-07-10 |
| Est. Completion | 2024-07-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05972174
The ClinicalTrials.gov registry entry for NCT05972174 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1,504 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which mRNA-1018 for H5N8 is the first listed.
NCT05972174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05972174 about?
NCT05972174 is a clinical study titled "A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults". The purpose of this Phase 1/2 study is to generate sufficient safety and immunogenicity data of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large Phase 3 trial with one selected vaccine candidate. The study will be conducted in 2 P...
What is the current status of trial NCT05972174?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,504 participants. The study started on 2023-07-10. Estimated completion is 2024-07-16.
What interventions are being tested in trial NCT05972174?
The interventions under investigation include: mRNA-1018 for H5N8 (BIOLOGICAL), mRNA-1018 for H7N9 (BIOLOGICAL), mRNA-1018 for H5 Only (BIOLOGICAL), mRNA-1018 for H7 Only (BIOLOGICAL), mRNA-1018 for H5 Only-CG (BIOLOGICAL).
Who is sponsoring clinical trial NCT05972174?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.